Liver Injury Associated with the Selective Progesterone Modulator Ulipristal Einar S. Björnsson Commentary 09 October 2020 Pages: 1201 - 1204
Assessing the Safety of COVID-19 Vaccines: A Primer Helen Petousis-Harris Current Opinion 30 September 2020 Pages: 1205 - 1210
Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease Tamara Y. MilderSophie L. StockerJerry R. Greenfield Leading Article 23 October 2020 Pages: 1211 - 1221
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology Fernanda Tavares-Da-SilvaOlivia MahauxJens-Ulrich Stegmann Leading Article Open access 30 August 2020 Pages: 1223 - 1234
Current Evidence on Abuse and Misuse of Gabapentinoids Staffan HäggAnna K. JönssonJohan Ahlner Review Article Open access 28 August 2020 Pages: 1235 - 1254
Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis Kelcie WitgesLeigh Anne ShaferCharles N. Bernstein Systematic Review 04 August 2020 Pages: 1255 - 1266
An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids Sarah KangAllen BrinkerMark I. Avigan Original Research Article 09 July 2020 Pages: 1267 - 1276
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis Milo GattiElisabetta PoluzziEmanuel Raschi Original Research Article Open access 03 August 2020 Pages: 1277 - 1285
Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review Gabrielle KornmannFrançois Curtin Original Research Article 13 August 2020 Pages: 1287 - 1296
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients Gianluca TrifiròMarco MassariITA-COVID-19: RAAS inhibitor group Original Research Article 27 August 2020 Pages: 1297 - 1308
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports Alem ZekariasSarah WatsonBirgitta Grundmark Original Research Article Open access 25 September 2020 Pages: 1309 - 1314
Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study Philippe GarciaAlexis RevetFrançois Montastruc Original Research Article 19 October 2020 Pages: 1315 - 1322